ReviewCurrent opinion in microbiology2020
Antifungal drug screening: thinking outside the box to identify novel antifungal scaffolds.
Review in Current opinion in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Compound Z247611722 Exhibits Antifungal Activity by Inhibiting Serine Palmitoyltransferase.Nature communications · 2026Article
- A geometric and probabilistic framework for mechanistic antifungal screening from colony morphology.Pest management science · 2026Article
- A novel pan-fungal screening platform for antifungal drug discovery: proof of principle study.Antimicrobial agents and chemotherapy · 2025Article
- Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025Review
- Article
- Green Chemistry andRecent advances in anti-infective drug discovery · 2024Article
- Transcriptional Reprogramming ofJournal of fungi (Basel, Switzerland) · 2023Article
- Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.Journal of fungi (Basel, Switzerland) · 2023Article
- Triazine-Based Small Molecules: A Potential New Class of Compounds in the Antifungal Toolbox.Pathogens (Basel, Switzerland) · 2023Article
- Searching for new antifungals for the treatment of cryptococcosis.Revista da Sociedade Brasileira de Medicina Tropical · 2023Review
- The Symbiotic FungusInsects · 2022Review
- Article
- Metamorphic Protein Folding Encodes Multiple Anti-Pathogens (Basel, Switzerland) · 2021Article
- In Silico Predicted Antifungal Peptides: In Vitro and In Vivo Anti-Journal of fungi (Basel, Switzerland) · 2021Article
- The Future of Antifungal Drug Therapy: Novel Compounds and Targets.Antimicrobial agents and chemotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Invasive fungal infections are responsible for a significant disease burden worldwide. Drugs to treat these infections are limited to only four unique classes, and despite these available treatments, mortality rates remain unacceptably high. In this review, we will discuss antifungal drug screening and how the approach to identifying novel compounds needs move away from traditional growth-based assays in order to meet the demand for new drugs. We highlight specific examples of creative screening strategies that increase the likelihood of identifying compounds with desired activities and provide perspective to inspire development of novel screens for the identification of first-in-class antifungals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.